NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDDK E-161-2014-0-EP-06 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF EP National Stage 15730666.3 Issued
NIDDK E-161-2014-0-DE-13 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF DE EP 15730666.3 Issued
NIDDK E-161-2014-0-FR-14 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FR EP 15730666.3 Issued
NIDDK E-161-2014-0-GB-15 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GB EP 15730666.3 Issued
NIDDK E-161-2014-0-US-07 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF US National Stage 15/317,864 10202367 Issued PDF
NIDDK E-161-2014-0-PCT-02 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PCT PCT PCT/US2015/035658 Expired
NIDDK E-161-2014-0-CN-05 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF CN National Stage 201580042841.1 Abandoned
NIDDK E-161-2014-0-IN-08 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF IN National Stage 201747000614 Abandoned
NIDDK E-161-2014-0-JP-09 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF JP National Stage 2017-518037 Abandoned
NIDDK E-161-2014-0-VN-12 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF VN National Stage 1-2017-00101 Abandoned
NIAID E-202-2015-0-US-01 METHODS FOR TREATING CEREBRAL EDEMA AND RESTORING BLOOD-BRAIN BARRIER INTEGRITY US 62/175,000 Abandoned
NIDDK E-161-2014-0-AU-03 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF AU National Stage 2015274333 Abandoned
NIDDK E-161-2014-0-CA-04 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF CA National Stage 2951924 Abandoned
NIDDK E-161-2014-0-KR-10 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF KR National Stage 10-2017-7000826 Abandoned
NIAID E-067-2012-0-US-03 HIV THERAPEUTICS AND METHODS OF MAKING AND USING SAME US National Stage 14/651,635 9775895 Abandoned PDF
NCI E-267-2014-0-US-01 PROCESS FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS US 62/173,777 Abandoned
NCI E-215-2014-0-US-03 Combination Therapies Using Agents That Target Tumor-Associated Stroma or Tumor Cells and Tumor Vasculature US National Stage 15/317,069 11034757 Issued PDF
NCI E-215-2014-7-US-03 COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS US National Stage 15/317,074 11033621 Issued PDF
NCI E-215-2014-5-US-03 COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND MICROTUBULES US National Stage 15/317,067 11033620 Issued PDF
NCI E-215-2014-2-US-03 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND ALKYLATING AGENTS US National Stage 15/317,063 10799584 Issued PDF
NCI E-215-2014-6-US-03 COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND TOPOISOMERASE US National Stage 15/317,086 10758614 Issued PDF
NCI E-215-2014-3-US-03 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR ASSOCIATED STROMA OR TUMOR CELLS US National Stage 15/317,055 10758613 Issued PDF
NCI E-215-2014-1-US-03 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS US National Stage 15/317,079 10758526 Issued PDF
NCI E-215-2014-4-US-03 COMBINATION THERAPIES USING PLATINUM AGENTS AND AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS US National Stage 15/317,084 10434174 Issued PDF
NCI E-215-2014-3-PCT-02 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS PCT PCT PCT/US2015/034949 Expired
NCI E-215-2014-2-PCT-02 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR ASSOCIATED STROMA OR TUMOR CELLS AND ALKYLATING AGENTS PCT PCT PCT/US2015/034947 Expired
NCI E-215-2014-7-PCT-02 COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND TOPOISOMERASE PCT PCT PCT/US2015/034933 Expired
NCI E-215-2014-4-PCT-02 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS PCT PCT PCT/US2015/034924 Expired
NCI E-215-2014-5-PCT-02 COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND MICROTUBULES PCT PCT PCT/US2015/034917 Expired
NCI E-215-2014-6-PCT-02 COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND TOPOISOMERASE PCT PCT PCT/US2015/034908 Expired
NCI E-215-2014-0-PCT-02 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND TUMOR VASCULATURE PCT PCT PCT/US2015/034885 Expired
NICHD E-045-2014-0-PCT-02 TARGET ACTIVATED MICRODISSECTION PCT PCT PCT/US2015/034930 Expired
NHLBI E-188-2014-0-PCT-02 METHODS FOR DETECTION OF AN ANALYTE BY MOVEMENT OF TETHERED MICROPARTICLES PCT PCT PCT/US2015/034815 Expired
NCI E-215-2014-1-PCT-02 COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS PCT PCT PCT/US2015/034941 Expired
NCI E-192-2015-0-US-01 Generation Of Anti-Idiotype Therapeutics For B-cell Malignancies US 62/173,318 Abandoned
NCI E-141-2008-0-JP-29 Complexes Of IL-15 And IL-15R AIpha And Uses Thereof JP DIV 2015-115431 Abandoned
NCI E-054-2013-2-JP-10 IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES JP DIV 2015-115431 Abandoned
NIAMS E-073-2011-1-US-09 Blockade of TL1A-DR3 Interactions to Ameliorate T Cell Mediated Disease Pathology and Antibodies Thereof US DIV 14/733,695 Abandoned
NCI E-099-2014-0-AU-03 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF AU National Stage 2015269219 Issued
NCI E-099-2014-0-BE-16 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF BE EP 15803100.5 Issued
NCI E-099-2014-0-AT-15 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF AT EP 15803100.5 Issued
NCI E-099-2014-0-IT-23 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IT EP 15803100.5 Issued
NCI E-099-2014-0-LU-24 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF LU EP 15803100.5 Issued
NCI E-099-2014-0-IE-22 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IE EP 15803100.5 Issued
NCI E-099-2014-0-DE-18 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF DE EP 15803100.5 Issued
NCI E-099-2014-0-NL-25 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF NL EP 15803100.5 Issued
NCI E-099-2014-0-FR-20 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF FR EP 15803100.5 Issued
NCI E-099-2014-0-CH-17 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF CH EP 15803100.5 Issued
NCI E-099-2014-0-ES-19 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF ES EP 15803100.5 Issued
NCI E-099-2014-0-TR-26 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF TR EP 15803100.5 Issued